Company
Nuevocor Pte Ltd
Clinical-stage genetic medicines company developing gene therapies for inherited cardiomyopathies, using a mechanobiology approach that targets the mechanical stress signalling inside failing heart muscle cells rather than correcting the mutated gene directly. Lead asset NVC-001 is an AAV-delivered therapy for LMNA-related dilated cardiomyopathy, an aggressive genetic heart-muscle disease with no targeted treatment. Longevity relevance is disease-specific rather than general: it aims to halt progression of a condition that causes heart failure and early death in carriers, not to modify ageing biology broadly. Both Singapore HQ and incorporation as a Pte Ltd confirmed on the company site, so it meets limb (b) of the inclusion rule.
At a glance
- Listing
- Private, not listed
- Category
- Regenerative medicine
- Headquarters
- Singapore (1 North Buona Vista Link, #10-07 Elementum, Singapore 139691), with offices in Fort Washington, Pennsylvania, USA and Paris, France
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- Regenerative medicine
- Market
- Singapore
- Recent inflection
- On 10 June 2025 the company announced FDA clearance of its IND for NVC-001 in LMNA-related dilated cardiomyopathy, clearing the way for first-in-human clinical work. This followed the close of a US$45m Series B on 6 May 2025 raised to fund that clinical development, per the company's own newsroom (https://www.nuevocor.com/news).
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | Unlisted |
| Ticker | None |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Private |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Singapore (1 North Buona Vista Link, #10-07 Elementum, Singapore 139691), with offices in Fort Washington, Pennsylvania, USA and Paris, France
- Website
- www.nuevocor.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
On 10 June 2025 the company announced FDA clearance of its IND for NVC-001 in LMNA-related dilated cardiomyopathy, clearing the way for first-in-human clinical work. This followed the close of a US$45m Series B on 6 May 2025 raised to fund that clinical development, per the company's own newsroom (https://www.nuevocor.com/news).
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
Every entity profile on variis is sourced. Not investment advice.